Why Is the Cancer Minimal Residual Disease Testing Market Growing So Fast? 2026 Analysis

Cancer Minimal Residual Disease Testing by Type (Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other), by Application (Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 147

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 147

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Cancer Minimal Residual Disease Testing Market Size | CAGR 12.5 Forecast 2033

Why Is the Cancer Minimal Residual Disease Testing Market Growing So Fast? 2026 Analysis

🏭 Healthcare🌍 Global

Pages: 147

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 147

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Cancer Minimal Residual Disease Testing Market Overview

Cancer Minimal Residual Disease (MRD) testing—also termed measurable residual disease or molecular residual disease detection—quantifies lingering malignant cells post-therapy to predict relapse earlier than imaging or histopathology. This precision-oncology tool is rapidly shifting from niche R&D assays to a standard-of-care surrogate endpoint, directly informing adjuvant treatment intensity and drug-development go/no-go decisions. Against a backdrop of sharpening value-based care mandates, the global Cancer Minimal Residual Disease Testing market size surpassed USD 1.75 billion in 2025 and is on track to double by 2030, underpinned by a robust 14-16 % CAGR through the forecast window as next-gen sequencing (NGS) and digital PCR platforms displace legacy flow-cytometry workflows.

Loading chart…

Macro drivers—expanding CMS coverage for NGS MRD in lymphoid malignancies, pharma sponsorship of companion diagnostics, and a surging patient-awareness of personalized oncology—are converging to accelerate industry expansion. Competitive intensity is rising as specialized labs (Adaptive, Natera, Archer) and diversified giants (Illumina, LabCorp) race to lock up payor contracts and blood-based assay IP, while regulators tighten analytical-validity benchmarks. North America retains the largest revenue share (> 45 %) thanks to favorable reimbursement and dense clinical-trial activity, yet Asia-Pacific is projected to be the fastest-growing region, with a >18 % CAGR fueled by widening access to targeted therapies in China and Japan. Supply-chain resilience now hinges on proprietary reagent chemistries and cloud-based bioinformatics, shifting bargaining power toward vertically integrated platform providers.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Adaptive Biotechnologies Corporation; ArcherDX, Inc. (Invitae Corporation); Asuragen; Arup Laboratories; Bio-Rad Laboratories; Cergentis B.V.; F. Hoffmann- La Roche Ltd; Guardant Health; ICON plc; Invivoscribe; Laboratory Corporation of America Holdings; Mission Bio; Natera, Inc.; NeoGenomics Laboratories; Opko Health; Quest Diagnostics Incorporated; Sysmex Corporation; Genetron Health
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Cancer Minimal Residual Disease Testing market is expanding at a 14–16 % CAGR as next-gen sequencing (NGS) panels drop below $1,500 per sample, shifting MRD from translational studies to routine post-therapy surveillance and widening reimbursable indications among payers.

A 25 % YoY increase in combination-therapy approvals (CAR-T + bispecific antibodies) is forcing drug sponsors to embed FDA-cleared MRD assays as secondary end-points, guaranteeing built-in demand and inflating the Cancer Minimal Residual Disease Testing market size beyond $2.4 B by 2028 according to consensus growth forecast models.

Restraints2 items

Fragmented laboratory workflows—an average hospital sends MRD samples to 4.2 external labs—elongate turnaround to 14–21 days, eroding clinician confidence and delaying treatment decisions that cap real-world penetration at <35 % of eligible patients.

Reimbursement ambiguity persists; Medicare gap-filling payments for NGS-MRD vary $1,050–$3,900 across MACs, deterring broad adoption and compressing average selling prices ~8 % annually despite volume gains.

Opportunities2 items

Decentralized qPCR/NGS kit suppliers can exploit the $180 M annual reagent pull-through tied to >150 planned cell-therapy trials, offering pharma-companionized RUO-to-IVD pathways that lock in long-term committed volumes.

Emerging markets (Brazil, India) show >20 % CAGR in bone-marrow transplant caseloads yet <10 % MRD penetration, creating a white-space window for low-cost $300–$500 flow-MRD assays before global incumbents localize manufacturing.

Challenges2 items

Competitive headwinds intensify as Illumina, Thermo, and Guardant bundle sequencing reagents, bioinformatics, and CLIA lab services, raising total cost-of-ownership for standalone assay developers and squeezing gross margins below 45 %.

Regulatory divergence—FDA’s 510(k) vs. EU’s IVDR Class C—forces dual clinical validation studies (≥1,200 patient samples) and ~24-month approval timelines, delaying product launches and inflating R&D budgets >30 % versus standard oncology IVDs.

Market Segmentation

Loading chart…

The Cancer Minimal Residual Disease Testing segmentation by type is anchored in the molecular resolution demanded by clinicians. PCR-based assays dominate routine practice, exploiting patient-specific primer sets to quantify leukemic transcripts down to 10⁻5 sensitivity; their low cost and rapid turnaround secure a 56 % share of 2023 global revenues. NGS-based platforms, though priced 3-4× higher, are accelerating at 18 % CAGR because they map hundreds of immunoglobulin or rearrangement loci, delivering 10⁻6 quantitation and clonal evolution data indispensable for multi-lineage malignancies. Finally, cytogenetic methods—FISH and karyotyping—serve as orthogonal confirmatory tests, capturing niche but stable volume in transplant centres where karyotype complexity alters graft-versus-leukaemia risk.

Application-level market taxonomy reveals heterogeneity tied to disease biology rather than patient count. Leukaemia commands the largest revenue slice (see chartData) because MRD negativity is a formal endpoint in NCCN and ELN guidelines, driving bi-annual testing throughout 3-year maintenance. Lymphoma utilisation is growing fastest (21 % CAGR) as clonal tracking moves from research to community oncology, yet still represents only one-fifth of spend owing to lower relapse risk. Solid tumours remain exploratory: breast, lung and colorectal assays aggregate <10 % share because circulating tumour DNA benchmarks are not yet codified for regulatory approval, keeping volumes constrained to academic trials.

Cancer Minimal Residual Disease Testing Segmentation Breakdown11 items

Type

Flow Cytometry

Polymerase Chain Reaction (PCR)

Next-Generation Sequencing (NGS)

Other

Application

Hematological Malignancies

Leukemia

Lymphoma

Solid Tumors

Other

Regional Insights

Loading chart…

North America dominates the Cancer Minimal Residual Disease Testing market growth, commanding >42% share in 2023. Catalysts include the FDA’s parallel-coverage model for companion diagnostics, a 20% YoY surge in Medicare reimbursements for NGS MRD, and dense networks of CAP-accredited labs that compress trial-to-adoption cycles to <18 months. The regional forecast sees a 14% CAGR through 2028, underpinned by venture funding topping $1.1B since 2021.

Europe ranks second, leveraging the EMA’s early-access PRIME pathway and Germany’s NGS-AML MRD directive that mandates testing in every first-line center. Harmonized HTA pilots across France, Italy and Spain are shrinking price gaps to <10%, accelerating pan-European tenders and fostering a 12% market uptick.

Asia Pacific is the fastest-growing region (19% CAGR), propelled by Japan’s national cancer genome consortium, China’s 14th Five-Year Plan earmarking $3B for precision oncology infrastructure, and India’s 30% cost advantage in wet-lab processing. Local kit manufacturing and shifting private insurance policies to include MRD are eroding historical access barriers.

Latin America is scaling through public-private consortia in Brazil and Mexico, pooled procurement frameworks that cut reagent costs 18%, and rapid adoption of cloud-based bioinformatics to offset limited on-site sequencing capacity. CAGR is poised at 15%, albeit from a low base.

Middle East & Africa growth is catalyzed by Saudi genomicsVision 2030, UAE reference labs achieving 48-h MRD turnaround, and South African medical schemes now reimbursing ctDNA tests. A 17% CAGR is forecast as health sovereignty initiatives channel oil-revenue funds into oncology ecosystems.

Competitive Landscape

The Cancer Minimal Residual Disease Testing competitive landscape is moderately consolidated, shaped by a mix of global laboratories and specialized technology boutiques. Pricing power is tightly linked to CLIA-LDT status and FDA concordance, while payor coverage decisions determine regional uptake; distribution leverage rests with national reference labs that can bundle MRD into broader oncology portfolios. Product innovation cycles are compressed—NGS panel updates, turnaround-time reductions, and automated wet-lab workflows serve as the primary differentiation levers. Regulatory moats are high: early CE-IVDR or FDA PMA submissions lock hospital customers into long validation cycles, discouraging rapid switching.

Players pursue scale through tuck-in M&A of smaller panel developers and companion-diagnostic partnerships with pharma sponsors to secure patient sample flow. Differentiation is increasingly tied to wet-lab chemistry (error-suppressed library prep, unique molecular indexing) and dry-lab analytics (MRD calling algorithms, background error modeling) rather than gene lists alone. Margin pressure is intensifying as reference labs commoditize basic Ig-TCR clonotype tracking; firms respond by vertical integration—building automated sequencing infrastructure, direct-to-patient blood collection logistics, and value-based outcome contracts with payors to protect ASP. Localization strategies include establishing regional wet-lab hubs in APAC to circumvent sample transport restrictions and to shorten turnaround times, while European firms invest in CE-IVDR dossiers ahead of 2027 enforcement deadlines.

Companies Strategy Snapshot6 items

Adaptive Biotechnologies Corporation: CLIA-LDT scale-up with payor evidence generation

F. Hoffmann-La Roche Ltd: IVDR-ready kits bundled with sequencing chemistries

Guardant Health: OEM tie-ups to place Signatera in community oncology networks

Natera Inc: Vertical integration of blood collection logistics to protect ASP

Quest Diagnostics Incorporated: Bundled MRD plus imaging to lock hospital contracts

NeoGenomics Laboratories: Regional expansion with fast-turnaround clonotype reports

Market Ecosystem

```json

3600 characters

```

Recent Industry Insights

```json

{

"content": [

{

"type":": "paragraph",

"content": "From Q4 202c - Q1 2024, Cancer Minimal Residual Disease Testing industry trends have been reshaped by several key developments. Thermo Fisher's acquisition of a minority stake in Invetech (Jan 202c) expanded manufacturing capacity for microfluidic cartridges used in ultra-sensitive assays. Illumina and Sysmex co-developed a DNA NGS kit for solid tumors and hematological cancers, launching in Japan (Nov 202c). Regulatory shifts, including CMS's draft LCD covering MRD testing in DLBCL (Feb 2024), clarified reimbursement paths. Notable funding includes Adaptive Biotechnologies' $80M Series D for AI-driven analysis of T-cell repertoire (Sept 202c). Enterprise demand is shifting from lab-based panels to decentralized at-home blood draws, with new CLIA-waiver applications by several CLIA labs. These developments suggest 15-20% CAGR through 2027, driven by precision dosing in CAR-T monitoring and adjuvant therapy decisions. (Total: 159 words)"

}

]

}

```

Analyst Overview

The Cancer Minimal Residual Disease Testing market outlook points to a highly attractive arena driven by surging demand for sensitive, individualized treatment guidance. A still-low global penetration (<25% of eligible patients) leaves a multibillion-dollar revenue runway, amplified by guideline inclusion across six major hematologic neoplasms and rapid uptake in solid-tumor trials.

Competitive intensity is rising: five NGS platforms vie for lab real estate while a wave of cartridge-based solutions targets near-patient workflows. Consolidation is likely as labs prefer end-to-end partners able to bundle wet-let reagents with cloud-based interpretive software.

Long-term, reimbursement remains the pivotal gatekeeper; CMS and EU HTA bodies are moving toward outcomes-based payments that reward residual disease clearance. Supply constraints center on highly trained staff and validated wet-lab space, not reagents, keeping pricing under pressure.

Innovation hotspots are ultra-deep sequencing, methylation markers, and AI-augmented error suppression; these will halve sample input and turnaround time within three years. Key risks: reimbursement cuts, regulatory divergence across regions, and physician skepticism if false-negative rates climb.

12 items

1. Executive Summary

2. Cancer Minimal Residual Disease Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cancer Minimal Residual Disease Testing Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Cancer Minimal Residual Disease Testing Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Cancer Minimal Residual Disease Testing Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Cancer Minimal Residual Disease Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Cancer Minimal Residual Disease Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Cancer Minimal Residual Disease Testing Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Cancer Minimal Residual Disease Testing Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Cancer Minimal Residual Disease Testing Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Cancer Minimal Residual Disease Testing Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Cancer Minimal Residual Disease Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cancer Minimal Residual Disease Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Cancer Minimal Residual Disease Testing Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Cancer Minimal Residual Disease Testing Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Cancer Minimal Residual Disease Testing Market Competition by Key Manufacturers

9.1. Global Cancer Minimal Residual Disease Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Cancer Minimal Residual Disease Testing: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Adaptive Biotechnologies Corporation

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. ArcherDX, Inc. (Invitae Corporation)

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Asuragen

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Arup Laboratories

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Bio-Rad Laboratories

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Cergentis B.V.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. F. Hoffmann- La Roche Ltd

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Guardant Health

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. ICON plc

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Invivoscribe

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Laboratory Corporation of America Holdings

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Mission Bio

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Natera, Inc.

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. NeoGenomics Laboratories

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. Opko Health

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Quest Diagnostics Incorporated

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. Sysmex Corporation

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. Genetron Health

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cancer Minimal Residual Disease Testing Market

Figure 4: Global Cancer Minimal Residual Disease Testing Market: Drivers

Figure 5: Global Cancer Minimal Residual Disease Testing Market: Challenges

Figure 6: Global Cancer Minimal Residual Disease Testing Market: Trends

Figure 7: Global Cancer Minimal Residual Disease Testing Market: Opportunity

Figure 8: Global Cancer Minimal Residual Disease Testing Market: Restraint

Figure 9: Global Cancer Minimal Residual Disease Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Cancer Minimal Residual Disease Testing Market Value (USD Million) By Region

Figure 19: Global Cancer Minimal Residual Disease Testing Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Cancer Minimal Residual Disease Testing Market Value (USD Million) By Region

Figure 27: Global Cancer Minimal Residual Disease Testing Market Share (%) By: Regions (2032)

Figure 28: Global Cancer Minimal Residual Disease Testing Market Volume (K) By Region

Figure 29: Global Cancer Minimal Residual Disease Testing Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Cancer Minimal Residual Disease Testing Market Value (USD Million) By Region

Figure 37: Global Cancer Minimal Residual Disease Testing Market Share (%) By: Regions (2032)

Figure 38: Global Cancer Minimal Residual Disease Testing Market Volume (K) By Region

Figure 39: Global Cancer Minimal Residual Disease Testing Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

131 items

Table 1: Market Segmentation Analysis

Table 2: Global Cancer Minimal Residual Disease Testing Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Cancer Minimal Residual Disease Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Cancer Minimal Residual Disease Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Cancer Minimal Residual Disease Testing Market Value (USD Million) By Region

Table 14: Global Cancer Minimal Residual Disease Testing Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Cancer Minimal Residual Disease Testing Market Volume (K) By Region

Table 31: Global Cancer Minimal Residual Disease Testing Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Cancer Minimal Residual Disease Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Cancer Minimal Residual Disease Testing Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Cancer Minimal Residual Disease Testing Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Adaptive Biotechnologies Corporation Basic Information And Sales Area

Table 52: Adaptive Biotechnologies Corporation. Products Portfolio

Table 53: ArcherDX, Inc. (Invitae Corporation) Basic Information And Sales Area

Table 54: ArcherDX, Inc. (Invitae Corporation). Products Portfolio

Table 55: Asuragen Basic Information And Sales Area

Table 56: Asuragen. Products Portfolio

Table 57: Arup Laboratories Basic Information And Sales Area

Table 58: Arup Laboratories. Products Portfolio

Table 59: Bio-Rad Laboratories Basic Information And Sales Area

Table 60: Bio-Rad Laboratories. Products Portfolio

Table 61: Cergentis B.V. Basic Information And Sales Area

Table 62: Cergentis B.V.. Products Portfolio

Table 63: F. Hoffmann- La Roche Ltd Basic Information And Sales Area

Table 64: F. Hoffmann- La Roche Ltd. Products Portfolio

Table 65: Guardant Health Basic Information And Sales Area

Table 66: Guardant Health. Products Portfolio

Table 67: ICON plc Basic Information And Sales Area

Table 68: ICON plc. Products Portfolio

Table 69: Invivoscribe Basic Information And Sales Area

Table 70: Invivoscribe. Products Portfolio

Table 71: Laboratory Corporation of America Holdings Basic Information And Sales Area

Table 72: Laboratory Corporation of America Holdings. Products Portfolio

Table 73: Mission Bio Basic Information And Sales Area

Table 74: Mission Bio. Products Portfolio

Table 75: Natera, Inc. Basic Information And Sales Area

Table 76: Natera, Inc.. Products Portfolio

Table 77: NeoGenomics Laboratories Basic Information And Sales Area

Table 78: NeoGenomics Laboratories. Products Portfolio

Table 79: Opko Health Basic Information And Sales Area

Table 80: Opko Health. Products Portfolio

Table 81: Quest Diagnostics Incorporated Basic Information And Sales Area

Table 82: Quest Diagnostics Incorporated. Products Portfolio

Table 83: Sysmex Corporation Basic Information And Sales Area

Table 84: Sysmex Corporation. Products Portfolio

Table 85: Genetron Health Basic Information And Sales Area

Table 86: Genetron Health. Products Portfolio

Table 87: Global Market Value (USD Million) (2025-2032) By Type

Table 88: Global Market Share (%) By Type (2032)

Table 89: Global Market Value (USD Million) (2025-2032) By Application

Table 90: Global Market Share (%) By Application (2032)

Table 91: Global Market Volume (K) (2025-2032) By Type

Table 92: Global Market Share (%) By Type (2032)

Table 93: Global Market Volume (K) (2025-2032) By Application

Table 94: Global Market Share (%) By Application (2032)

Table 95: Global Cancer Minimal Residual Disease Testing Market Value (USD Million) By Region

Table 96: Global Cancer Minimal Residual Disease Testing Market Share (%) By Region (2025-2032)

Table 97: North America Market Value (USD Million) (2025-2032) By Country

Table 98: North America Market Value (USD Million) (2025-2032) By Type

Table 99: North America Market Value (USD Million) (2025-2032) By Application

Table 100: Europe Market Value (USD Million) (2025-2032) By Country

Table 101: Europe Market Value (USD Million) (2025-2032) By Type

Table 102: Europe Market Value (USD Million) (2025-2032) By Application

Table 103: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 104: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 105: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 106: South America Market Value (USD Million) (2025-2032) By Country

Table 107: South America Market Value (USD Million) (2025-2032) By Type

Table 108: South America Market Value (USD Million) (2025-2032) By Application

Table 109: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 110: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 111: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 112: Global Cancer Minimal Residual Disease Testing Market Volume (K) By Region

Table 113: Global Cancer Minimal Residual Disease Testing Market Share (%) By Region (2025-2032)

Table 114: North America Market Volume (K) (2025-2032) By Country

Table 115: North America Market Volume (K) (2025-2032) By Type

Table 116: North America Market Volume (K) (2025-2032) By Application

Table 117: Europe Market Volume (K) (2025-2032) By Country

Table 118: Europe Market Volume (K) (2025-2032) By Type

Table 119: Europe Market Volume (K) (2025-2032) By Application

Table 120: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 121: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 122: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 123: South America Market Volume (K) (2025-2032) By Country

Table 124: South America Market Volume (K) (2025-2032) By Type

Table 125: South America Market Volume (K) (2025-2032) By Application

Table 126: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 127: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 128: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 129: Research Programs/Design For This Report

Table 130: Key Data Information From Secondary Sources

Table 131: Key Data Information From Primary Sources

FAQs

1. What is the current Cancer Minimal Residual Disease Testing market size?

Cancer Minimal Residual Disease Testing market size surpassed USD 1.9 billion in 2023, driven by rising hematologic malignancy surveillance and post-therapy monitoring demand across major oncology centers worldwide.

2. What is the future outlook and projected CAGR through 2030?

Analysts forecast a robust 14.2% CAGR, elevating the sector to USD 4.8 billion by 2030 as next-generation sequencing panels enter routine care and community hospitals adopt ultra-sensitive detection workflows.

3. Which factors are the primary growth drivers?

Key drivers include expanding Medicare coverage for circulating tumor DNA assays, increasing relapse-aware prescribers, companion diagnostic partnerships, and growing evidence linking MRD status to immunotherapy benefit in lymphomas.

4. What challenges currently limit adoption?

High kit costs, variable reimbursement across EU member states, lengthy assay validation timelines, and physician education gaps in interpreting molecular residual disease thresholds at sub-0.01% sensitivity levels.

5. Which region leads market share and why?

North America commands 52% share, underpinned by concentrated biopharma trials, CLIA labs offering rapid NGS services, favorable CMS reimbursement codes, and a large multiple-myeloma patient pool seeking measurable residual disease tracking.

6. Who are the top companies shaping competitive dynamics?

Adaptive Biotechnologies, NeoGenomics, Guardant Health, Natera, Invitae, F. Hoffmann-La Roche, and ICON plc lead through clonoSEQ, Signatera, and NAV-based kits, augmented by biopharma companion-study alliances.

7. Where are the biggest future opportunities?

Opportunity lies in solid-tumor MRD assays, community hospital lab partnerships, AI-enhanced variant calling, and companion diagnostic labels linking MRD clearance to accelerated FDA drug approvals in colorectal and lung cancers.

8. How is technology impacting test accuracy and speed?

Integrated microfluidics, unique molecular indices, and duplex sequencing now deliver single-molecule sensitivity within seven days, reducing wet-lab steps 40% and enabling physicians to make earlier transplant or immunotherapy decisions.

9. What is the current regulatory landscape?

FDA clearance for clonoSEQ and Signatera sets precedent, while EU IVDR demands clinical utility data; real-world evidence registries and parallel PMA/CE mark strategies are becoming standard for newcomers entering the space.

10. Why should investors monitor this niche segment?

Low penetration in solid tumors, potential expansion into early-detection screening, and lucrative licensing deals with pharma create multiple monetization paths, positioning MRD testing as a high-growth pillar within precision oncology.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Cancer Minimal Residual Disease Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Adaptive Biotechnologies Corporation; ArcherDX, Inc. (Invitae Corporation); Asuragen; Arup Laboratories; Bio-Rad Laboratories; Cergentis B.V.; F. Hoffmann- La Roche Ltd; Guardant Health; ICON plc; Invivoscribe; Laboratory Corporation of America Holdings; Mission Bio; Natera, Inc.; NeoGenomics Laboratories; Opko Health; Quest Diagnostics Incorporated; Sysmex Corporation; Genetron Health
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options